Targeting NEAT1 with antisense oligonucleotides or siRNAs, in combination with established mTOR inhibitors such as everolimus, represents a promising dual‐approach strategy for the treatment of TSC‐related epilepsy. This evidence concerns the gene NEAT1 and tuberous sclerosis.